NCT03774758Recruiting
Biomarkers for Risk Stratification in Lung Cancer
Circulating Tumor DNA for Risk Stratification in Lung Cancer Screening
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1440 (estimated)
- First submitted
- 11 Dec 2018
- Start date
- 17 Dec 2017
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- University of California, San Francisco
- Diseases
- Lung cancer
- NCT number
- NCT03774758
What you commit to
- Study type: Observational
- Planned participants: 1440
- From 17 Dec 2017 to the primary completion date, 31 Dec 2030
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unstable heart conditions - defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy, or history of complications because of previous blood donation.
Other illness
- Active non-cutaneous malignancy within the past 5 years as per medical record or patient report.
- Severe Chronic Obstructive Pulmonary Disease (COPD) - defined by Gold Stage IV.
Lab values
- Malnourishment - determined by BMI less than 19. If subject has BMI greater or equal to 19, but has a history of malnourishment, study staff will measure albumin level of subject's blood after initial blood draw. Albumin level must be greater than 2.5 mg per deciliter, or subject will be excluded.
Other
- Exclusion criteria for possible follow-up visit blood draw:
- Anemia - measured by hematocrit level of less than 30%, measured after the first blood draw.
- Liver cirrhosis.
Who the study is looking for
- Age ≥ 40 years
- Ability to understand and provide written informed consent
- Willingness to comply with study protocols and provide blood samples.
- Willingness to complete 3-year clinical follow up
Age in the registry: 40 years to - · Sex: All
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
| Zuckerberg San Francisco General Hospital and Trauma Center Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
| San Francisco VA Medical Center Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.